Iambic Therapeutics, Inc. (IAM)

Iambic Therapeutics will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

Iambic Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	18.25	9.43	1.19
Revenue Growth	-	689.45%	-
Gross Profit	18.25	9.43	1.19
Selling, General & Admin	-	14.25	9.38
Research & Development	-	77.53	45.7
Operating Expenses	-	91.78	55.07
Operating Income	-100.19	-82.35	-53.88
Interest Expense (Income)	-6.05	-5.19	-6.03
Other Expense (Income)	0.07	0.09	-
Pretax Income	-94.2	-77.25	-47.84
Income Tax	0.05	0.05	0.03
Net Income	-94.25	-77.3	-47.88

Additional Metrics

Year Ending	TTM	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-68.17	-60.1	-34.27
Free Cash Flow Growth	-	-	-
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-548.93%	-873.65%	-4512.31%
Profit Margin	-516.39%	-820.02%	-4009.80%
Free Cash Flow Margin	-373.50%	-637.63%	-2869.93%
EBITDA	-98.87	-81.22	-52.82
EBITDA Margin	-541.73%	-861.61%	-4423.62%
Depreciation & Amortization	1.38	1.23	1.06
EBIT	-100.25	-82.44	-53.88
EBIT Margin	-549.29%	-874.60%	-4512.31%